Emotional support may slow ovarian cancer

	Tweet

Among women with advanced Ovarian cancer, those with more psychosocial support may fare better, US researchers suggest.

They found that women with a strong support system have lower levels of a pro-inflammatory compound, interleukin-6 (IL-6), in the blood. High levels of IL-6 have been linked to faster progression and shorter survival with this malignancy.

“It’s relatively unusual for cancer studies looking at psychosocial factors to also look at relationships in the tumor microenvironment,” said Dr. Susan K. Lutgendorf, from the University of Iowa in Iowa City.

The findings, reported in the medical journal Cancer are based on a study of 61 women who completed surveys regarding social support, distressed mood, and quality of life before undergoing surgery for Ovarian cancer. Pre-operative blood samples as well as abdominal fluid (i.e., from the tumor environment) obtained during surgery were tested for IL-6 levels.

Social attachment was linked to lower blood levels of IL-6, the report indicates. Conversely, poorer health-related quality of life was tied to higher IL-6 levels.

Similar findings were seen with IL-6 levels in abdominal fluid.

“Our findings suggest that lowering IL-6 levels around the tumor may be one possible mechanism by which psychosocial support has a beneficial effect on Ovarian cancer,” Lutgendorf concluded.

SOURCE: Cancer, July 15, 2005.

RELATED STORIES:
Younger women survive ovarian cancer better   Young early stage ovarian cancer patients can preserve fertility   Ovarian cancer drug trial reveals promising new treatment   Researchers Identify Genes Tied to Deadliest Ovarian Cancers   Ovarian Cancer Study Gets Aid   New drug comb may lengthen ovarian cancer survival   Ovarian Cancer: the Not-so-silent Killer   FDA clears biomarker test for ovarian cancer   Ovarian cancer screening popular despite guidelines   OHSU Primate Center’s Ovarian Cancer Finding May be a “Win-Win” for At-Risk Women Who Wish to Have a Family   Late-Stage Ovarian Cancer Therapy Shows Promise in Phase I Trial   Abdominal chemotherapy boosts survival in ovarian cancer patients   Short-term OC use cuts ovarian cancer risk   Ovarian cancer subtypes are different diseases: Implications for biomarker studies   Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers   Analgesic drugs don’t reduce ovarian cancer risk   Angiogenesis Linked to Poor Survival in Patients with Rare Type of Ovarian Cancer   Birth control pill lowers ovarian cancer risk - study   Faulty proteins may prove significant in identifying new treatments for ovarian cancer   2 studies find new genetic links to ovarian cancer risk   PET-CT Highly Accurate for Detecting Ovarian Cancer Recurrence   Biological diversity of ovarian cancer lessens value of screening

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]